Celldex Therapeutics (NASDAQ:CLDX) has received mixed ratings from 5 analysts in the last three months, with 1 bullish, 3 somewhat bullish, and 1 indifferent. The average 12-month price target is now $53.4, down from $63.50, with a high estimate of $80.00 and a low of $27.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Celldex focuses on immunotherapy technologies and cancer-targeting biologics, with clinical trials for various cancers. Despite impressive revenue growth of 272.73%, the company's net margin and ROE are below industry averages, and it has a conservative debt-to-equity ratio of 0.01.